Antiphospholipid syndrome: suspect, prove, anticoagulate
When to think of it
Clot in an unusual site.
Stroke or heart attack in a young patient.
A new clot while on apixaban or rivaroxaban.
A fetal death at 10 weeks or later.
Delivery before 34 weeks for preeclampsia or a failing placenta.
Low platelets. Lupus.
Livedo (net-like purple skin). Thick heart valves.
The diagnosis: one event, one test, twice
Positive in all three is called triple positive: the highest-risk profile. Tests 2 and 3 are antibody tests and can be drawn on any anticoagulant. The event and the positive test must fall within 5 years of each other (2006 criteria) or 3 years (2023 criteria).
Who gets what
INR is the clotting-time ratio used to dose warfarin.
Against warfarin, direct oral anticoagulants tripled new clots, mostly arterial.5 randomized trials, 624 patients: 29 clots against 10, Peto odds ratio 3.01; arterial 5.5; venous no different (Adelhelm 2023). A direct oral anticoagulant is a fallback only for venous, not triple-positive disease when warfarin is impossible or the INR cannot be kept in range.
Pregnancy
Pregnancy complications only, no clot ever
Prior clot, on warfarin
Warfarin harms the embryo from week 6 and is safe during breastfeeding. Direct oral anticoagulants are not used in pregnancy. A positive test with no events: aspirin may be considered. When losses continue despite treatment: raise enoxaparin to full dose, or add hydroxychloroquine, or add low-dose prednisolone in the first trimester. In women with antibodies and recurrent losses, heparin plus aspirin raised live births over aspirin alone (risk ratio 1.27; 5 trials, 1,295 women; low-certainty evidence); for enoxaparin-type heparin alone the estimate was 1.20.
Classification criteria are not a diagnosis
- The 2023 ACR/EULAR criteria (American College of Rheumatology and European League Against Rheumatism) score six clinical and two laboratory domains and need 3 points in each.
- Built for research: 99% specific but 84% sensitive, against 86% and 99% for the 2006 criteria. A patient who misses them can still need treatment.
- How often the tests are positive, by event: stroke 13.5%, heart attack 11%, deep vein thrombosis 9.5%, pregnancy complications 6% (median across 120 studies).
Catastrophic antiphospholipid syndrome
- Clots in three or more organs within days, usually small vessels: kidney, lung, brain. Under 1% of patients with the syndrome, often after an infection.
- Death in 37% of 522 episodes in the international registry.
- Treatment is combined from the start: heparin + glucocorticoids + plasma exchange or immunoglobulin.
Check yourself: antiphospholipidA 38-year-old has an unprovoked femoral clot. The lupus anticoagulant comes back positive the day after rivaroxaban was started. Diagnosis made?
No. Rivaroxaban causes false-positive lupus anticoagulant results, and one test is never enough. Send anticardiolipin and anti-beta-2 glycoprotein I now (reliable on any anticoagulant), and repeat at 12 weeks. Repeat the lupus anticoagulant off anticoagulant, or ask the lab for a DOAC-neutralized assay; many labs can do this.
Sources
Retrieved from PubMed (abstracts and full text), read on Oct 15, 2026.
- Miyakis S, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome. J Thromb Haemost 2006. doi:10.1111/j.1538-7836.2006.01753.x
- Barbhaiya M, et al. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Ann Rheum Dis 2023. doi:10.1136/ard-2023-224609
- Andreoli L, et al. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis. Arthritis Care Res 2013. doi:10.1002/acr.22066
- Devreese KMJ, et al. Update of the guidelines for lupus anticoagulant detection and interpretation (ISTH). J Thromb Haemost 2020. doi:10.1111/jth.15047
- Tektonidou MG, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019. doi:10.1136/annrheumdis-2019-215213
- Zuily S, et al. Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: ISTH guidance. J Thromb Haemost 2020. doi:10.1111/jth.14935
- Adelhelm JBH, et al. Therapy with direct oral anticoagulants for secondary prevention of thromboembolic events in the antiphospholipid syndrome: systematic review and meta-analysis of randomised trials. Lupus Sci Med 2023. doi:10.1136/lupus-2023-001018
- Pengo V, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome (TRAPS). Blood 2018. doi:10.1182/blood-2018-04-848333
- Woller SC, et al. Apixaban compared with warfarin in thrombotic antiphospholipid syndrome (ASTRO-APS). Blood Adv 2022. doi:10.1182/bloodadvances.2021005808
- Pengo V, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile. Blood 2011. doi:10.1182/blood-2011-03-340232
- Sammaritano LR, et al. 2020 ACR guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 2020. doi:10.1002/art.41191
- Hamulyák EN, et al. Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss. Cochrane Database Syst Rev 2020. doi:10.1002/14651858.CD012852.pub2
- Rodríguez-Pintó I, et al. Catastrophic antiphospholipid syndrome: descriptive analysis of 500 patients from the international registry. Autoimmun Rev 2016. doi:10.1016/j.autrev.2016.09.010
A patient with anemia: two numbers first
Step 1: is the marrow trying?
Bleeding: find the source.
Hemolysis: LDH (lactate dehydrogenase) up, haptoglobin down, indirect bilirubin up, smear, direct antiglobulin (Coombs) test.
Go to step 2: the size of the cell.
Correct the count for the anemia: reticulocyte % × (patient's hematocrit ÷ 45). A haptoglobin of 25 mg/dL or less was 96% specific for hemolysis (Marchand 1980).
Step 2: how big are the cells?
Small cells
Saturation is transferrin saturation. Ferritin of 30 or less: 92% sensitive, 98% specific for iron deficiency (Mast 1998).
Normal-size cells, reticulocytes low
- First tests: ferritin and saturation, creatinine, B12 and folate, smear (look at the other cell lines).
- Usual answers: inflammation or cancer; kidney disease (too little erythropoietin); marrow (chemotherapy, infiltration, aplasia).
- Iron and B12 deficiency together can average out to a normal MCV. The clue is a high RDW (red cell distribution width): small and large cells mixed.
Large cells
Treating each one
IV when oral fails or cannot work: malabsorption, ongoing loss, kidney disease, chemotherapy, heart failure, or no time.
Neurologic signs: injections, 1 mg every other day until no further improvement.
IV ferric carboxymaltose dropped phosphate below 2 mg/dL in 74 to 75% of patients; ferric derisomaltose (iron isomaltoside) in 8%.Two randomized trials, 245 patients (Wolf 2020). Check phosphate with repeated doses.
When to transfuse
MINT, 3,504 patients: death or reinfarction at 30 days 16.9% with a threshold of 7 to 8 against 14.5% with a threshold of 10 (risk ratio 1.15, not significant, but the direction favored more blood). AABB 2023 made no recommendation for acute coronary syndrome.
Check yourself: anemiaHemoglobin 8.9, MCV 92, ferritin 210, saturation 12%, on palliative chemotherapy for colon cancer. Does she need iron?
Probably, but look for bleeding first: in colon cancer a saturation of 12% can be true iron loss from the tumor. Either way the marrow is short of iron, and with ferritin 100 to 299 and saturation under 20% she meets the definition. IV iron is reasonable. If bleeding is excluded, the anemia is from the chemotherapy and hemoglobin stays under 10 after iron, erythropoietin becomes an option (next tab).
Sources
Retrieved from PubMed (abstracts and full text), read on Oct 15, 2026.
- Mast AE, et al. Clinical utility of the soluble transferrin receptor and comparison with serum ferritin in several populations. Clin Chem 1998. PubMed 9550557.
- Ko CW, et al. AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia. Gastroenterology 2020. doi:10.1053/j.gastro.2020.06.046
- Aapro M, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol 2018. doi:10.1093/annonc/mdx758
- McDonagh TA, et al. 2023 focused update of the 2021 ESC guidelines for heart failure. Eur Heart J 2023. doi:10.1093/eurheartj/ehad195
- Mentzer WC. Differentiation of iron deficiency from thalassaemia trait. Lancet 1973. doi:10.1016/s0140-6736(73)91446-3
- Marchand A, et al. The predictive value of serum haptoglobin in hemolytic disease. JAMA 1980. PubMed 7365971.
- Devalia V, et al. Guidelines for the diagnosis and treatment of cobalamin and folate disorders. Br J Haematol 2014. doi:10.1111/bjh.12959
- Stabler SP. Vitamin B12 deficiency. N Engl J Med 2013. doi:10.1056/NEJMcp1113996
- Stoffel NU, et al. Iron absorption from oral iron supplements given on consecutive versus alternate days. Lancet Haematol 2017. doi:10.1016/S2352-3026(17)30182-5
- von Siebenthal HK, et al. Alternate day versus consecutive day oral iron supplementation in iron-depleted women: a randomized trial. EClinicalMedicine 2023. doi:10.1016/j.eclinm.2023.102286
- Wolf M, et al. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia (PHOSPHARE). JAMA 2020. doi:10.1001/jama.2019.22450
- Wang H, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev 2018. doi:10.1002/14651858.CD004655.pub3
- Miller JW, et al. Excess folic acid and vitamin B12 deficiency: clinical implications? Food Nutr Bull 2024. doi:10.1177/03795721241229503
- Carson JL, et al. Red blood cell transfusion: 2023 AABB international guidelines. JAMA 2023. doi:10.1001/jama.2023.12914
- Carson JL, et al. Restrictive or liberal transfusion strategy in myocardial infarction and anemia (MINT). N Engl J Med 2023. doi:10.1056/NEJMoa2307983
Erythropoietin: who can, who cannot
Cancer: can this patient receive it?
In myeloma, lymphoma and chronic lymphocytic leukemia, first watch how the hemoglobin responds to the cancer treatment itself. Epoetin alfa, darbepoetin and the biosimilars are considered equivalent.
The label says no
Uncontrolled hypertension
Blood pressure rises on treatment.
Pure red cell aplasia after a previous course
Antibodies against erythropoietin.
A serious allergic reaction to the product
Before, to the same drug.
Multiple-dose vials in pregnancy, breastfeeding and infants
They contain benzyl alcohol. Use single-dose vials.
Once started
When it does not work, look for progression and iron deficiency.
The trade
Heart failure: iron yes, erythropoietin no
Across 6 trials and 7,175 patients, IV iron cut heart failure admissions plus cardiovascular death by about a fifth. Overall survival did not change.Risk ratio 0.81 over full follow-up, 0.72 in the first year; all-cause death hazard ratio 0.92, not significant (Anker 2025, including FAIR-HF2, IRONMAN, HEART-FID and AFFIRM-AHF).
Kidney disease is a different rule
- In chronic kidney disease the indication is the kidney, not chemotherapy: on dialysis, start when hemoglobin is 9 to 10 or lower; off dialysis, start by symptoms; in both, keep hemoglobin below 11.5 (KDIGO 2026, the kidney guideline group).
- With active cancer or a cancer history, KDIGO asks for a shared decision rather than a protocol; in practice the oncology rules on this tab win. The new HIF stabilizer pills (daprodustat, vadadustat) are not used in active cancer.
- TREAT, darbepoetin to a hemoglobin of 13 in diabetic kidney disease: strokes doubled (hazard ratio 1.92). Among those with a past cancer, 14 of 188 died of cancer against 1 of 160 (post hoc).
- The FDA restricted-prescribing program for oncology ended in April 2017. The boxed warning remains.
Check yourself: erythropoietinStage II colon cancer on adjuvant FOLFOX, hemoglobin 9.2, ferritin 180, saturation 15%. Epoetin?
No: curative intent. Give IV iron, transfuse if symptomatic.
Sources
Retrieved from PubMed (abstracts and full text), the KDIGO guideline and FDA labeling, read on Oct 15, 2026.
- Bohlius J, et al. Management of cancer-associated anemia with erythropoiesis-stimulating agents: ASCO/ASH clinical practice guideline update. J Clin Oncol 2019. doi:10.1200/JCO.18.02142
- Tonia T, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012. doi:10.1002/14651858.CD003407.pub5
- Bohlius J, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009. doi:10.1016/S0140-6736(09)60502-X
- Henke M, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy. Lancet 2003. doi:10.1016/S0140-6736(03)14567-9
- Leyland-Jones B, et al. Maintaining normal hemoglobin levels with epoetin alfa in metastatic breast cancer (BEST). J Clin Oncol 2005. doi:10.1200/JCO.2005.06.150
- Swedberg K, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure (RED-HF). N Engl J Med 2013. doi:10.1056/NEJMoa1214865
- Heidenreich PA, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Circulation 2022. doi:10.1161/CIR.0000000000001063
- McDonagh TA, et al. 2023 focused update of the 2021 ESC guidelines for heart failure. Eur Heart J 2023. doi:10.1093/eurheartj/ehad195
- Anker SD, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency (FAIR-HF). N Engl J Med 2009. doi:10.1056/NEJMoa0908355
- Anker SD, et al. Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency. Nat Med 2025. doi:10.1038/s41591-025-03671-1
- Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease (TREAT). N Engl J Med 2009. doi:10.1056/NEJMoa0907845
- Babitt JL, et al. Executive summary of the KDIGO 2026 clinical practice guideline for anemia in chronic kidney disease. Kidney Int 2026. doi:10.1016/j.kint.2025.06.005
- FDA label: epoetin alfa (Epogen, Procrit, Retacrit), contraindications and boxed warning, revised December 2024.
Melanoma: who needs the node, who needs more than surgery
Sentinel node: read the thickness
T is the thickness category of the staging system (AJCC 8th edition); "a" means not ulcerated, "b" ulcerated.
Positive sentinel node: watch, do not dissect
Completion dissection against ultrasound: melanoma-specific survival 86% in both arms at 3 years. Lymphedema 24% against 6%.MSLT-II, 1,934 patients (Faries 2017). Dissection did improve control in the node basin (92% against 77%). DeCOG-SLT found no survival difference at 6 years.
More than surgery?
Pembrolizumab and nivolumab are PD-1 blockers. Stage IIIA with a sentinel deposit of 1 mm or less was not studied in the adjuvant trials; larger IIIA deposits had a small absolute benefit. Discuss it.
What it buys
No PD-1 blocker or BRAF/MEK trial has yet shown longer overall survival against placebo.Adjuvant ipilimumab did (5-year survival 65% against 54%, EORTC 18071), at the cost of 42% severe immune toxicity, and it is no longer used. CheckMate 238 compared nivolumab with that ipilimumab: survival similar at 9 years (hazard ratio 0.88). Dabrafenib + trametinib: 0.80, P = 0.06. KEYNOTE-054 has not reported survival.
Recurrence is what these drugs change; survival is still open.
The price
Nivolumab in stage IIB/IIC (CheckMate 76K): hormone therapy needed in 14.9% against 1.5% with placebo; hypothyroidism 12.2%, adrenal insufficiency 2.3%. Endocrine events, except hyperthyroidism, were the ones that had not resolved at data cutoff. Pembrolizumab in stage III (KEYNOTE-054): severe treatment-related events 14.7% against 3.4%.
Not standard yet
- Personalized mRNA vaccine plus pembrolizumab. In the randomized phase 2 trial (157 patients) recurrence fell (hazard ratio 0.56, P = 0.053; 0.51 at 5 years). The phase 3 trial (1,137 patients, stage IIB to IV) was announced positive for recurrence and distant metastasis in a company press release in August 2026, without published data or approval.
- Neoadjuvant pembrolizumab alone. SWOG S1801 (phase 2, stage IIIB to IVC): 2-year event-free survival 72% against 49%.
Check yourself: melanomaMelanoma 1.6 mm, ulcerated, sentinel node negative. Adjuvant immunotherapy?
No. That is T2b N0, stage IIA. Adjuvant trials started at IIB (above 2 mm with ulceration, or above 4 mm). The sentinel node was still worth doing: a positive node would have made it stage III and changed the answer.
Check yourself: melanomaA 3 cm groin node, biopsy-proven melanoma, no distant disease. Surgery first?
Increasingly, no. Two doses of ipilimumab plus nivolumab first, then surgery: 2-year event-free survival 77% against 56% with surgery then nivolumab (NADINA). It is off-label, so document the discussion.
Sources
Retrieved from PubMed (abstracts and full text), FDA approval notices and congress abstracts, read on Oct 15, 2026.
- Gershenwald JE, et al. Melanoma staging: evidence-based changes in the AJCC eighth edition. CA Cancer J Clin 2017. doi:10.3322/caac.21409
- Wong SL, et al. Sentinel lymph node biopsy and management of regional lymph nodes in melanoma: ASCO and SSO guideline update. J Clin Oncol 2018. doi:10.1200/JCO.2017.75.7724
- Cordeiro E, et al. Sentinel lymph node biopsy in thin cutaneous melanoma: a systematic review and meta-analysis. Ann Surg Oncol 2016. doi:10.1245/s10434-016-5137-z
- Han D, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. J Clin Oncol 2013. doi:10.1200/JCO.2013.50.1114
- Morton DL, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma (MSLT-I). N Engl J Med 2014. doi:10.1056/NEJMoa1310460
- Faries MB, et al. Completion dissection or observation for sentinel-node metastasis in melanoma (MSLT-II). N Engl J Med 2017. doi:10.1056/NEJMoa1613210
- Leiter U, et al. Final analysis of DeCOG-SLT trial. J Clin Oncol 2019. doi:10.1200/JCO.18.02306
- Eggermont AMM, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy (EORTC 18071). N Engl J Med 2016. doi:10.1056/NEJMoa1611299
- Eggermont AMM, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (KEYNOTE-054). N Engl J Med 2018. doi:10.1056/NEJMoa1802357
- Eggermont AMM, et al. Seven-year analysis of adjuvant pembrolizumab in the EORTC1325/KEYNOTE-054 trial. Eur J Cancer 2024. doi:10.1016/j.ejca.2024.114327
- Ascierto PA, et al. Nivolumab for resected stage III or IV melanoma at 9 years (CheckMate 238). N Engl J Med 2026. doi:10.1056/NEJMoa2504966
- Long GV, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma (COMBI-AD). N Engl J Med 2017. doi:10.1056/NEJMoa1708539
- Long GV, et al. Final results for adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med 2024. doi:10.1056/NEJMoa2404139
- Luke JJ, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716). Lancet 2022. doi:10.1016/S0140-6736(22)00562-1
- Luke JJ, et al. KEYNOTE-716 4-year update. Eur J Cancer 2025. doi:10.1016/j.ejca.2025.115381
- Kirkwood JM, et al. Adjuvant nivolumab in resected stage IIB/C melanoma (CheckMate 76K). Nat Med 2023. doi:10.1038/s41591-023-02583-2
- Blank CU, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma (NADINA). N Engl J Med 2024. doi:10.1056/NEJMoa2402604
- Lucas MW, et al. NADINA 2-year update. ESMO Congress 2025, abstract LBA57.
- Patel SP, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma (SWOG S1801). N Engl J Med 2023. doi:10.1056/NEJMoa2211437
- Weber JS, et al. Individualised neoantigen therapy mRNA-4157 plus pembrolizumab versus pembrolizumab in resected melanoma (KEYNOTE-942). Lancet 2024. doi:10.1016/S0140-6736(23)02268-7
- Khattak MA, et al. KEYNOTE-942 5-year update. J Clin Oncol 2026. doi:10.1200/JCO-26-00835
Ifosfamide encephalopathy: stop, hydrate, methylene blue
Why it happens
Cyclophosphamide makes much less of this metabolite and rarely causes encephalopathy. Methylene blue is thought to stand in for the blocked mitochondrial enzymes and to reduce formation of the toxic metabolite.
What it looks like
Who is at risk
Kidney and albumin
Higher creatinine and low albumin. Giving albumin does not prevent it.
Prior cisplatin
Odds 12 times higher in the Dana-Farber series.
Other drugs
Opioids (odds 2.8), CYP2B6 inhibitors (5.2). The antiemetics aprepitant and netupitant: suspected, not proven.
The patient and the bag
Pelvic or bulky abdominal disease, poor performance status, a previous episode, some generic formulations.
At the bedside
How good is the evidence?
Pelgrims 2000: 12 patients, not randomized. Treatment was not assigned at random, so the two groups are not comparable.
Recent data are still case series. At MD Anderson (2025), 19 of 20 treated patients recovered; with preventive methylene blue at rechallenge, 3 of 5 had it again.24 patients aged 4 to 30. A 2025 review from a European sarcoma reference center: no randomized trial, mixed results, still used for severe cases because there is no better option. A 2026 case report rescued a patient who worsened on methylene blue with continuous dialysis.
Methylene blue: before you order it
SSRI and SNRI are serotonin (and norepinephrine) reuptake inhibitors such as sertraline and venlafaxine; MAOI are monoamine oxidase inhibitors. Use in this setting is off-label. Urine turns blue-green, and pulse oximetry reads falsely low for a while. For the next cycle, many centers give methylene blue 50 mg every 6 to 8 hours from the day before ifosfamide. Changing the alkylating drug is a decision for the disease team: cyclophosphamide is not interchangeable in every regimen.
Check yourself: ifosfamideDay 2 of ifosfamide, sarcoma, on sertraline and oxycodone, now drowsy. What first?
Stop the bag, fluids, glucose and sodium; methylene blue only if not clearing, and with sertraline plus oxycodone on board the serotonin risk is real: review before ordering.
Sources
Retrieved from PubMed (abstracts and full text) and FDA labeling, read on Oct 15, 2026.
- Torchia A, et al. A narrative review on diagnosis and treatment of ifosfamide-induced encephalopathy, the perspective of a EURACAN reference center for sarcomas. Front Pharmacol 2025. doi:10.3389/fphar.2025.1512966
- Alqahtani S, et al. Ifosfamide-induced encephalopathy in children and young adults: the MD Anderson Cancer Center experience. Cancers 2025. doi:10.3390/cancers17132192
- Szabatura AH, et al. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. J Oncol Pharm Pract 2015. doi:10.1177/1078155214527143
- Kettle JK, et al. Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy. Pharmacotherapy 2010. doi:10.1592/phco.30.8.812
- Chambord J, et al. Ifosfamide-induced encephalopathy: brand-name vs generic formulation. J Clin Pharm Ther 2019. doi:10.1111/jcpt.12823
- Pinilla Rello A, et al. Ifosfamide-induced encephalopathy and concomitant use of netupitant/palonosetron. Eur J Hosp Pharm 2025. doi:10.1136/ejhpharm-2025-004493
- Pelgrims J, et al. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer 2000. doi:10.1054/bjoc.1999.0917
- Idle JR, Beyoğlu D. Ifosfamide: history, efficacy, toxicity and encephalopathy. Pharmacol Ther 2023. doi:10.1016/j.pharmthera.2023.108366
- Menon A, et al. Rare delayed ifosfamide encephalopathy. Case Rep Oncol 2024. doi:10.1159/000535952
- Khan BSA, Din Bashir S. Treating acute toxo-metabolic encephalopathy with continuous renal replacement therapy: ifosfamide neurotoxicity. Cureus 2026. doi:10.7759/cureus.103244
- FDA label: methylene blue injection (ProvayBlue), boxed warning on serotonin syndrome with serotonergic drugs and opioids, revised May 2025; FDA Drug Safety Communication, 2011.
- FDA label: ifosfamide (Ifex), neurotoxicity.